Insulin‑like growth factor axis: A potential nanotherapy target for resistant cervical cancer tumors (Review)

Oncol Lett. 2023 Feb 10;25(3):128. doi: 10.3892/ol.2023.13714. eCollection 2023 Mar.

Abstract

Cervical cancer is among the most frequently occurring neoplasms worldwide, and it particularly affects individuals in developing countries. Factors such as the low quality of screening tests, the high incidence of locally advanced cancer stages and the intrinsic resistance of certain tumors are the main causes of failure in the treatment of this neoplasm. Due to advances in the understanding of carcinogenic mechanisms and bioengineering research, advanced biological nanomaterials have been manufactured. The insulin-like growth factor (IGF) system comprises multiple growth factor receptors, including IGF receptor 1. These receptors are activated by binding to their respective growth factor ligands, IGF-1 and IGF-2, and insulin, and play an important role in the development, maintenance, progression, survival and treatment resistance of cervical cancer. In the present review, the role of the IGF system in cervical cancer and three nanotechnological applications that use elements of this system are described, namely Trap decoys, magnetic iron oxide nanoparticles and protein nanotubes. Their use in the treatment of resistant cervical cancer tumors is also discussed.

Keywords: cervical cancer resistance; insulin-like growth factor axis; nanotherapy; theranostic.

Publication types

  • Review

Grants and funding

This work was supported by the Research Support of the Polytechnic University of the Valley of Mexico.